{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:14:54Z","timestamp":1790806494479,"version":"4.1.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tazemetostat represents the first epigenetic therapy approved for the treatment of follicular lymphoma (FL). It inhibits the activity of the enhancer of zeste homolog 2 (EZH2) histone methyltransferase, the first of a multitude of epigenetic regulators that have been identified as recurrently mutated in FL and germinal center diffuse large B-cell lymphoma. In this review, we discuss the initial discovery and ongoing exploration of the functional role of EZH2 mutations in lymphomagenesis. We also explore the path from the preclinical development of tazemetostat to its approval for the treatment of relapsed FL, and potential future therapeutic applications. We discuss the clinical data that led to the approval of tazemetostat and ongoing research into the function of EZH2 and of tazemetostat in lymphomas that derive from the germinal center, which could increase the applicability of this drug in the future.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002773","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T09:49:16Z","timestamp":1619603356000},"page":"2256-2263","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Treating lymphoma is now a bit EZ-er"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-7800","authenticated-orcid":false,"given":"Ryan D.","family":"Morin","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Arthur","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, BC, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-7868","authenticated-orcid":false,"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Jewish General Hospital, McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"2","key":"2021042715323915700_B1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"2","key":"2021042715323915700_B2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2021042715323915700_B3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"key":"2021042715323915700_B4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13148-016-0245-y","article-title":"Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients","volume":"8","author":"Pera","year":"2016","journal-title":"Clin Epigenetics"},{"issue":"16","key":"2021042715323915700_B5","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/blood-2011-11-366062","article-title":"Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies","volume":"119","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2021042715323915700_B6","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2021042715323915700_B7","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","article-title":"Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study","volume":"116","author":"Jardin","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2021042715323915700_B8","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"issue":"9","key":"2021042715323915700_B9","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2007-03-082511","article-title":"Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6","volume":"110","author":"Mottok","year":"2007","journal-title":"Blood"},{"issue":"20","key":"2021042715323915700_B10","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7360","key":"2021042715323915700_B11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"12","key":"2021042715323915700_B12","doi-asserted-by":"crossref","first-page":"e28585","DOI":"10.1371\/journal.pone.0028585","article-title":"EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas","volume":"6","author":"Ryan","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"2021042715323915700_B13","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood.V97.12.3896","article-title":"Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma","volume":"97","author":"van Kemenade","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2021042715323915700_B14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ni876","article-title":"Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement","volume":"4","author":"Su","year":"2003","journal-title":"Nat Immunol"},{"issue":"2","key":"2021042715323915700_B15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/genetics\/75.2.299","article-title":"The interaction of two complex loci, zeste and bithorax in Drosophila melanogaster","volume":"75","author":"Kaufman","year":"1973","journal-title":"Genetics"},{"issue":"1","key":"2021042715323915700_B16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/genetics\/126.1.185","article-title":"Genetic analysis of the enhancer of zeste locus and its role in gene regulation in Drosophila melanogaster","volume":"126","author":"Jones","year":"1990","journal-title":"Genetics"},{"issue":"41","key":"2021042715323915700_B17","doi-asserted-by":"crossref","first-page":"27757","DOI":"10.1074\/jbc.M804442200","article-title":"Dominant alleles identify SET domain residues required for histone methyltransferase of Polycomb repressive complex 2","volume":"283","author":"Joshi","year":"2008","journal-title":"J Biol Chem"},{"issue":"49","key":"2021042715323915700_B18","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2021042715323915700_B19","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2021042715323915700_B20","doi-asserted-by":"crossref","first-page":"e83737","DOI":"10.1371\/journal.pone.0083737","article-title":"Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2021042715323915700_B21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/leu.2013.288","article-title":"EZH2 in normal and malignant hematopoiesis","volume":"28","author":"Lund","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2021042715323915700_B22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"7427","key":"2021042715323915700_B23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"11","key":"2021042715323915700_B24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"4","key":"2021042715323915700_B25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2021042715323915700_B26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response","volume":"37","author":"B\u00e9guelin","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"2021042715323915700_B27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"2021042715323915700_B28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2020.01.006","article-title":"EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas","volume":"119","author":"Otsuka","year":"2020","journal-title":"Mol Immunol"},{"issue":"4","key":"2021042715323915700_B29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of mhc deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"19","key":"2021042715323915700_B30","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2021042715323915700_B31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021042715323915700_B32","article-title":"Tazverik (tazemetostat) tablets, for oral use: US prescribing information","author":"Epizyme Inc","year":"2020"},{"issue":"11","key":"2021042715323915700_B33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"2021042715323915700_B34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"2021042715323915700_B35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.12.006","article-title":"Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma","volume":"126","author":"Batlevi","year":"2020","journal-title":"Eur J Cancer"},{"key":"2021042715323915700_B36","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed\/refractory follicular lymphoma","author":"Morschhauser","year":"","journal-title":"Lancet Oncol"},{"issue":"11","key":"2021042715323915700_B37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2021042715323915700_B38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma [published correction appears in J Clin Oncol. 2019;37(16):1448]","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"35","key":"2021042715323915700_B39","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [published correction appears in J Clin Oncol. 2018;36(5):521]","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021042715323915700_B40","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115132","article-title":"Updated report on identification of molecular predictors of tazemetostat response in an ongoing NHL phase 2 study [abstract]","volume":"132","author":"McDonald","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2021042715323915700_B41","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/bloodadvances.2020001646","article-title":"The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL","volume":"4","author":"Assouline","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2021042715323915700_B42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1292]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2021042715323915700_B43","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2021042715323915700_B44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2021042715323915700_B45","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113411","article-title":"Interim results from an ongoing phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) [abstract]","volume":"132","author":"Ribrag","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2021042715323915700_B46","doi-asserted-by":"crossref","first-page":"e111840","DOI":"10.1371\/journal.pone.0111840","article-title":"Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas","volume":"9","author":"Knutson","year":"2014","journal-title":"PLoS One"},{"issue":"13","key":"2021042715323915700_B47","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/1078-0432.CCR-19-3741","article-title":"A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features","volume":"26","author":"Sarkozy","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7577","key":"2021042715323915700_B48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"2021042715323915700_B49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hon.203_2631","article-title":"Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large B-cell lymphoma: primary analysis of a phase 1B study [abstract]","volume":"37","author":"Palomba","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"2021042715323915700_B50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021042715323915700_B51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"issue":"20","key":"2021042715323915700_B52","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2020002580","article-title":"Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes","volume":"4","author":"Scholze","year":"2020","journal-title":"Blood Adv"},{"issue":"s","key":"2021042715323915700_B53","article-title":"Opportunity for therapeutic expansion in mantle cell lymphoma: tazemetostat combination synergy status in preclinical MCL models [abstract]","volume":"78","author":"Hood","year":"2018","journal-title":"Cancer Res"},{"issue":"19","key":"2021042715323915700_B54","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2256\/1806053\/advancesadv2020002773c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2256\/1806053\/advancesadv2020002773c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T09:49:56Z","timestamp":1619603396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/8\/2256\/475823\/Treating-lymphoma-is-now-a-bit-EZ-er"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002773","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]}}}